Ixazomib citrate
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
163 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 30 | 66 | 11 | 7 | 10 | 105 |
| Plasma cell neoplasms | D054219 | — | — | 20 | 39 | 10 | 6 | 8 | 72 |
| Neutropenia | D009503 | — | D70 | — | — | — | 1 | — | 1 |
| Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | — | 1 | — | 1 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | — | — | — | 1 | — | 1 |
| Febrile neutropenia | D064147 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyloidosis | D000686 | EFO_1001875 | E85 | 4 | 4 | 1 | — | 1 | 7 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | 1 | 1 | — | 1 | 4 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 2 | 3 | 1 | — | — | 4 |
| Frailty | D000073496 | — | R53.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 12 | 10 | — | — | — | 17 |
| Neoplasms | D009369 | — | C80 | 8 | 2 | — | — | — | 10 |
| Leukemia | D007938 | — | C95 | 5 | 4 | — | — | — | 8 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 5 | 3 | — | — | 1 | 7 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 5 | 1 | — | — | — | 5 |
| Lymphoid leukemia | D007945 | — | C91 | 5 | 1 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 5 | — | — | — | 5 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 3 | — | — | — | 5 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 2 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 4 | — | — | — | 4 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute disease | D000208 | — | — | 2 | — | — | — | — | 2 |
| Poems syndrome | D016878 | EFO_1001115 | — | 1 | — | — | — | — | 1 |
| Pathologic complete response | D000095384 | — | — | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Neurofibrosarcoma | D018319 | — | — | 1 | — | — | — | — | 1 |
| Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | — | — | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paraproteinemias | D010265 | — | D47.2 | — | — | — | — | 1 | 1 |
| Abnormal karyotype | D059786 | — | — | — | — | — | — | 1 | 1 |
| Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
No data
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
478 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use